Showing 1681-1690 of 3038 results for "".
- Nordic Pharma Launches Authorized Generic of Maxitrolhttps://modernod.com/news/nordic-pharma-launches-authorized-generic-of-maxitrol/2482759/Nordic Pharma announced a partnership with Harrow to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone ophthalmic suspension), for the treatment and relief of bacterial eye infections. Maxitrol and generic equivalents had a
- Nordic Pharma Presents Data and Patient Experience Study for Lacrifill Canalicular Gel at ASCRShttps://modernod.com/news/nordic-pharma-presents-data-and-patient-experience-study-for-lacrifill-canalicular-gel-at-ascrs/2482756/Nordic Pharma will be presenting recently published patient data and patient experience study for Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the ASCRS annual meeting in Los Angeles. The April issue of Ca
- MST Enters Strategic Partnership with Mani to Distribute Ophthalmic Surgical Blade Portfolio in the UShttps://modernod.com/news/microsurgical-technology-mst-enters-strategic-partnership-with-mani-to-distribute-ophthalmic-surgical-blade-portfolio-in-the-us/2482739/Microsurgical Technology (MST) announced a strategic partnership with Mani Inc. under which MST will serve as a distributor of Mani’s ophthalmic surgical blade portfolio in the United States. The deal is supported by the establishment of Mani Medical America, the US
- Nordic Pharma Receieves CE Mark Approval for Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-receieves-ce-mark-approval-for-lacrifill-canalicular-gel/2482729/Nordic Group, the parent company of Nordic Pharma, announced that its dry eye therapy Lacrifill has received CE mark approval. This regulatory milestone, which Nordic says was achieved several months ahead of schedule, allows Nordic Pharma to introduce Lacrifill across Europea
- Call for Nominations: Prevent Blindness Seeks to Honor Leaders in Vision Healthhttps://modernod.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/Prevent Blindness, one of the nation’s largest eye health and safety nonprofit organizations, issued their call for nominations for the “
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscopehttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope/2482634/Norlase announced the FDA 510(k) clearance and CE Mark for Norlase LYNX, which the company describes as the world’s first and only pattern scanning laser indirect ophthalmoscope. Commercially available now, the LYNX is battery-powered and provides surgeons the abili
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg
- EssilorLuxottica Acquires Espansione Group, Provider of Noninvasive Ophthalmic Medical Deviceshttps://modernod.com/news/essilorluxottica-acquires-espansione-group-provider-of-noninvasive-ophthalmic-medical-devices/2482581/Optical giant EssilorLuxottica announced it is acquiring Italy-based Espansione Group, a provider of noninvasive medical devices for the diagnosis and treatment of dry eye, ocular surface and retinal diseases. Financial terms of the deal were not disclosed. Esp
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio